5 June 2023

We’re kicking off the week by announcing our continued support of Manus Neurodynamica as part of a £2.6m funding round alongside co-investors Northstar Ventures UKSIS Ventures Old College Capital and Scottish Enterprise

In December 2021 Manus received Breakthrough Device Designation from the FDA for its NeuroMotor Pen, a medical device to aid diagnosis and monitoring of neuromotor disorders including Parkinson's disease. Manus was also recently selected by Johnson & Johnson to utilise the NeuroMotor Pen in immunotherapy use cases for detection of neuromotor adverse effects following CAR T-cell therapy.

This funding round will enable Manus to further its reach into the EU retail pharmacy sector and pursue FDA regulatory clearance in the US later this year with market entry targeted for early 2024.

Congratulations to the Manus team: Rutger ZietsmaAlbert Nicholl